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Introduction
The bradykinin (BK)-related peptides known as the kinins stimulate the B 1 receptor (B 1 R) and the B 2 receptor (B 2 R) that are mainly coupled to protein G q and related second messenger systems, like calcium [21] . The official nomenclature BK B 1 R is somewhat misleading because BK has negligible affinity for this receptor type that is rather responsive to des-arginine 9 -bradykinin (des-Arg 9 -BK) and Lys-des-Arg 9 -BK. Unlike that of the widely distributed and preformed B 2 Rs, the expression of B 1 Rs is induced under inflammatory or tissue injury conditions. Both kinin receptor subtypes are found in vascular and renal cells, but also in nervous, connective and intestinal tissues and some types of leukocytes [21] .
Thousands of kinin receptor ligands have been produced, both peptides and nonpeptides [24, 12, 10] . In the present paper, we illustrate a strategy for the development of new peptide analogs based on two premises: 1) for both subtypes of BK receptors, current docking models for agonist and antagonist peptides alike predict that the C-terminus of the peptide interacts with receptor transmembrane domains deep in the central rosette formed by the receptor transmembrane domains, and the N-terminus rather binds to negatively charged residues of an extracellular loop [21] . Thus, N-terminal extensions of peptide ligands should protrude out of the receptor into extracellular fluid. 2) Available pharmacologic data for both receptor subtypes suggest that Nterminal extension has only a mild effect on affinity. For instance, the natural agonist sequence
Met-Lys-BK exhibits a slightly decreased affinity for the recombinant human and mouse B 2 Rs relative to that of BK [23] . Maximakinin, a natural sequence isolated from amphibian skin, is composed of the full BK sequence at its C-terminal region with a 10-residue N-terminal extension (DLPKINRKGPRPPGFSPFR); this peptide has pharmacological activity in mammalian tissues [27, 7] (see also section 3.1.1). N-terminal extension of both agonist and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   5 antagonist B 1 R ligands is illustrated by development of the high affinity radioligand [
I]-Tyr-
Gly-Lys--aminocaproyl-Lys-des-Arg 9 -BK [22] , successfully used in tumor autoradiography [25] , or of the highly potent antagonist B-10324 (2,3,4,5,6-pentafluorocinnamoyl-B-9958) [16] .
In this paper we review the properties of a series of recently produced and characterized kinin receptor ligands. One systematically pursued purpose was to develop the full complement of fluorescent agonists and antagonists for both receptor subtypes and for a major BK-inactivating enzyme, angiotensin converting enzyme (ACE). However, other cargoes were also introduced at the N-terminus of specific peptides in part to test the idea of functional cargoes targeted to receptors by the peptide structure ( Fig. 1 , Table 1 ). Much of the presented material is original (Figs. 2-4 , 5B, 5C, 6-8 and parts of Table 2 ) and consolidated with previously published data to survey this research front .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   6 2. Methods
Peptide synthesis
The novel ligands containing 5(6)-carboxyfluorescein (CF) or other N-terminal extensions based on the condensation of carboxylic acids are listed in Table 1 (full sequences given). Their modular building blocks are illustrated in Fig. 1 . They were synthesized under solid phase form, purified and characterized using general methods described elsewhere [13] . Two novel peptides . BK and Lys-des-Arg 9 -BK were purchased from Bachem Bioscience (King of Prussia, PA).
Radioligand binding competition assays
Three radioligands were exploited as described to determine affinity of novel peptides by competition to recombinant or natural B 2 Rs ([1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 Local ethics review boards approved the use of animals in the present project and of segments of human umbilical cords obtained following elective cesarean sections; informed consent was obtained in the latter case. The isolated rabbit aorta is an established bioassay for the B 1 R that has been exploited to characterize novel B 1 R agonists or antagonists [4] ; B 2 R ligands were assayed by the contraction of the human isolated umbilical vein [5, 3, 14] . Cumulative concentration effect curves were constructed for novel agonists and their potencies estimated by the halfmaximal concentration (EC 50 ) and compared to that of reference agonists of natural sequence for each receptor subtype. Antagonists were introduced 30 min before the construction of the concentration-effect curves of the reference agonist (BK for the B 2 R, des-Arg 9 -BK for the B 1 R) and the shift to the right was used to determine their potencies using the Schild regression and pA 2 scale [3, 4] .
Calcium mobilization
FURA-2 fluorometry was applied to detached cells as described [4] to assess the effects of some novel ligands on kinin receptor signaling.
Microscopy
Epifluorescence of CF-or AlexaFluor-350-labeled peptides and of green fluorescent protein (GFP)-tagged molecules (B 2 R-GFP -arrestin 2 -GFP, the early endosome marker EEA1-FYVE-GFP [6]) was observed (epifluorescence microscopy, 400-1000 ×). In cells transiently expressing a recombinant BK receptor, treatments with fluorescent peptides were carried out at 37°C for 30 min in the regular culture medium, followed by ample washings and observation. In addition,
confocal sections of cells grown on a glass surface were also taken using a Volocity spinning disk confocal microscope (Improvision, PerkinElmer) equipped with a Hamamatsu EMCCD digital 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8 camera. Three-dimensional reconstitutions of cells from series of confocal images were made using the FreeSFP software (http://www.svi.nl).
Immunoblots
HEK 293 cells stably expressing B 2 R-GFP [18] were treated with drugs for 12 h, lyzed and the immunoblots for B 2 R-GFP were performed as previously reported [5] based on the monoclonal anti-GFP antibody JL8 (Clontech, Palo Alto, CA). Fig. 2B ), by contractility of the human isolated umbilical vein for both peptides (Fig. 1D ) and by B-10618-induced persistent internalization of the fusion protein B 2 R-GFP (Fig. 2C) , although the conjugates were hundreds of times less potent The massive loss of affinity of BK sequences prolonged at their N-terminus is not an inescapable fatality: a way out may have been naturally selected. Maximakinin, an ingredient of an animal venom, has only lost approximately one log of potency at the B 2 R assays represented in table 2 [7]. Whether Gly-Pro at the N-terminus of the BK sequence has a role in spatially orienting the N-terminal extension out the B 2 R surface is an intriguing possibility. Maximakinin may inspire the future design of B 2 R agonist ligands. (Table 2 ) [3] , supporting that antagonists bind to the B 2 Rs in a manner that is significantly different from that of BK [19] . However, the use of D-biotinyl-BK (B-10330) bound eptavidin-AlexaFluor-594 [3] , suggesting that the N-terminal biotinyl moiety of B-10330 may not protrude out of the receptor 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 -BK-induced contraction of the rabbit isolated aorta with a pA 2 of 5.95 [3] . The conditions of the human umbilical vein contractility assay make it highly selective for the B 2 R because the reference agonist BK has virtually no affinity for human B 1 Rs [19, 17] .
B 2 R antagonists
B
B 1 R ligands
The reference high affinity ligands for the B 1 Rs were Lys-des-Arg 9 -BK (agonist) and B-9958 Tables 1, 3 ). CF addition at the N-terminus of the antagonist led to moderate affinity loss (5-6-fold at rabbit receptors, 33-fold at the human recombinant receptors), whether or -10372, B-10376, respectively). As for B 2 R ligands, the loss of affinity for the fluorescent B 1 R agonist was more severe that for the antagonists (24-fold at rabbit receptors, ~200-fold at the human recombinant receptors, B-10378
being CF--Lys-des-Arg (Fig. 1, table 1) . In vitro pharmacological studies in the rabbit isolated aorta evidenced a minor loss of potency relative to the parent peptide that is entirely compensated by the resistance of the N-terminally extended B-9958 analogs to aminopeptidase N present in the tissue (Table 3 ) [15, 16] . This is shown by the lack of potentiation of B-10324 by a concurrent treatment of tissues with the aminopeptidase N inhibitor amastatin, while the potency of the parent peptide B-9958 increases 7-fold in the presence of amastatin. B-10324 exhibits antitumoral activity in a prostate cancer xenotransplantation model [16] . It remains to be seen whether the F5c moiety adds to the cytotoxicity of B-10324, or simply confers metabolic stability in vivo.
N-terminal extension of B 2 R agonists leads to resistance to endosomal inactivation
The agonist-activated B 2 R is subjected to phosp -arrestin binding and endocytosis; the co-internalized BK is then rapidly degraded in the endosome and the receptor population is largely recycled in ~1 h or less parallel to its dephosphorylation [21] . A recent 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 finding based on the use of alternate B 2 R agonists exploited to trigger endocytosis was that the resistance of the agonist to degradation is a major determinant of this cycling. This has been discovered with the agonist peptide B-9972 and confirmed with a nonpeptide partial agonist drug structurally derived from an antagonist, compound 47a [5, 2] . These two agents structurally integrate resistance to many or all peptidases that may inactivate BK (amino-, carboxy-and endopeptidases) and they forced the endocytosis of B 2 Rs for more than 12 h, with consequences -arrestins with endosomes, prolonged signalling (e.g., ERK1/2 phosphorylation) and measurable receptor downregulation (degradation) over 12 h. The synthesis of BK analogs with modifications limited to their N-terminus only is theoretically far less protective relative to the multiple possible sites of attack by peptidases in the BK sequence, as
shown by the virtually equal affinities of BK and of CF--BK for the carboxydipeptidase ACE (Table 2) . Nevertheless, we now appreciate that BK analogs with an extended N-terminus more or less completely recapitulate the effect of B-9972 on B 2 R cycling, as shown by the prolonged (12 h) endocytosis induced by maximakinin [7] and the downregulation of the B 2 R-GFP fusion protein (with detection of free GFP in the cell lysate) following 12 h treatments with maximakinin or CF--BK [7] . B-10618, another BK sequence modified at its N-terminus, has an intermediary behavior: based on free GFP accumulation, the chlorambucil conjugate B-10618 also downregulated B 2 R-GFP at 100 nM, but less effectively than an equimolar concentration of B-9972 (Fig. 2E ). This concentration of B-10618 promoted prolonged endocytosis (Fig. 2C ), but little calcium signalling or smooth muscle contraction (Fig. 2B, D) .
The consistent effect of the N-terminal protection on B 2 R-GFP degradation supports that the major inactivation route of BK in endosomes is a form of aminopeptidase that indirectly controls 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 15 inactivation is different from that seen in the fetal bovine serum-containing culture medium, where ACE dominates and determines a BK half-life of less than 10 min [1] .
Fluorescent ligands to probe kinin receptor adaptation
We present three-dimensional reconstitutions of single representative cells based on series of confocal sections (Fig. 5) . [14] . Further, intracellular colocalization with the early endosome marker EEA1-FYVE-GFP is also supported by the novel blue light-emitting AF350--BK (Fig. 6B) . The activated B 2 R also recruits the other non-visual arrestin isoform, as judged by the colocalization of the blue emitting agonist -arrestin 2 -GFP in the same limited focal depth of the image (Fig. 6B ). 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   17 fig . 5C ). The same findings applied to cells expressing the human B 1 R (data not shown). This may be compatible with receptor migration to caveolae and indicates a more subtle mode of agonist-induced receptor translocation than that of the related B 2 R.
Modeling the endosomal inactivation of BK using three fluorescent analogs
The fluorescent BK analog CF--BK not only stimulates and internalizes B 2 Rs, but also models the endocytic degradation of BK: as a function of time, but as early as 30 min after application, smooth cytosolic labeling with the free green fluorophore is observed as the punctuate staining of stimulated cell decreases [14] (Fig. 6A, 7B ). This translocation of the fluorescence from endosomes to cytosol is blocked by cell co-treatment with bafilomycin A1, the inhibitor of the proton pump that acidifies endosome, lysosomes and other organelles [14] . The novel analogue FTC-B-9972 provides an opportunity to corroborate this model, as the parent peptide induces a very prolonged B 2 -arrestins to endosome presumably due to its persistence in endosomes [2] . The agonist FTC-B-9972, on the average, effectively produced more apparent fluorescent endosomal structures per cell and less cytosolic staining than CF--BK used at equimolar concentration in the same lots of HEK 293 cells transiently expressing a recombinant B 2 R (Fig. 7B) . The third fluorescent B 2 R agonist, AF350--BK, is inherently less efficacious than the others to label receptor-expressing cells because blue fluorophores are relatively ineffective and their signal/noise ratio is not as good due to the maximal cell autofluorescence in this region of the spectrum. Nevertheless, AF350--BK also models the endosomal inactivation of BK in a distinctive manner: bafilomycin pretreatment increases both the number of labeled endosomal structures and the intensity of the punctuate labeling in cells that expressed recombinant B 2 Rs (Fig. 8) . There was no cytosolic accumulation 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 18 of the free fluorophore, a molecule that may diffuse out of the cells, be too diluted for detection or blend with cell autofluorescence.
Imaging ACE
ACE is not a receptor, but nevertheless binds BK as a substrate, and is the target of an important drug class, the ACE inhibitors. It is of interest that CF--BK, being identical to BK at its Cterminus, is recognized by ACE equally well ( Fig. 6A ) [14] . The fluorescent antagonist B-10380 is a discriminative fluorescent probe of B 2 Rs at 50 nM, failing to label recombinant ACE [14] .
Prospect for functional cargoes
Fluorophore-labeled BK receptor ligands illustrate perfectly well that the peptide part of the molecule can target the conjugate to cells expressing the corresponding receptor type, and to the endosomal compartment if a B 2 R agonist is the parent peptide. The easy release of fluorophores from a given B 2 R agonist design, but not from another (section 3.4), suggests that one can program at will the release of a drug-like cargo or its intracellular retention, thus conferring novel properties to BK receptors. We have presented some alternate carboxylic acid cargoes (Fig. 1 , Tables 1, 2 
Conclusions and perspectives
The sequences of kinin receptor ligands have a moderate tolerance for N-terminal extension to accommodate useful cargoes, but the pharmacological identity of the parent peptide is always kept in the prolonged peptides. Specifically, there is room for improvement in the design of fluorescent receptor probes, given the existence of brighter and more stable fluorophores than fluorescein and the occasional severe loss of receptor affinity (typically more so for the agonists).
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Figure legends

